Journal of Clinical Oncology
Articles in this Issue
Real-world clinical outcomes among metastatic colorectal cancer (mCRC) patients with liver metastases who received trifluridine/tipiracil (FTD/TPI) or FTD/TPI + bevacizumab (FTD/TPI+bev) combination therapy.
60 Background: FTD/TPI+bev has shown clinical benefit compared with FTD/TPI monotherapy in clinical trials and was approve...
Effect of initial corticosteroid doses and second-line immunosuppressants on overall duration of corticosteroid therapy for immune-related adverse events in gastrointestinal tumors.
824 Background: Immune checkpoint inhibitors (ICIs) have improved survival in patients with cancer but can also cause immu...
Tumor-informed ctDNA monitoring during surveillance for early detection of recurrence in patients with stage II/III esophageal cancer treated with chemoradiation.
440 Background: The recurrence rate in patients with esophageal cancer (EC) is high, with up to 50% recurring within 2 yea...
Real-world outcomes of systemic therapy in patients with hepatocellular carcinoma and decompensated Child-Pugh C cirrhosis.
490 Background: Patients with hepatocellular carcinoma (HCC) and decompensated cirrhosis (Child-Pugh C) have a poor progno...
A phase 2 randomized study comparing telisotuzumab adizutecan monotherapy with standard of care in patients with post-adjuvant circulating tumor DNA-positive colorectal cancer.
TPS265 Background: Curative intent standard of care (SOC) management of colorectal cancer (CRC) involves surgical tumor re...
Phase II study of tinengotinib in advanced cholangiocarcinoma: Analysis of molecular response and resistance mechanisms.
566 Background: FGFR inhibitors (FGFRi) have an established role in treating FGFR2-altered (alt) cholangiocarcinoma (CCA)....
Outcomes for incurable anal cancer according to HIV status.
2 Background: The incidence of anal cancer continues to rise in the United States, with an increasing proportion of patien...
Significance of atypical peritoneal cytology in patients with locally advanced gastric cancer.
454 Background: While positive peritoneal cytology is associated with worse clinical outcomes in patients with gastric can...
Geographic distribution and equity in access to gastrointestinal cancer clinical trials in the United States.
807 Background: Geographic access to clinical trials is critical for equitable cancer care. Gastrointestinal (GI) cancers—...
A framework for contextual mass categorization leveraging explainable AI.
657 Background: Large healthcare systems often use a centralized radiology report database which facilitates data mining f...
Diagnostic yield of germline genetic testing for early-onset colorectal cancer in a safety-net healthcare system.
88 Background: Germline genetic testing (GGT) is recommended for all individuals with early-onset colorectal cancer (eoCRC...
Efficacy and safety of liposomal irinotecan in patients with advanced pancreatic cancer: A prospective, multicenter, real-world study.
720 Background: Liposomal irinotecan, a liposome-encapsulated form of irinotecan, effectively improves drug stability, pre...
Cadonilimab plus chemotherapy versus PD-1 inhibitor plus chemotherapy as first-line (1L) treatment for advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS <5: A propensity-matched, retrospective cohort study.
407 Background: Although PD-1 inhibitors plus chemotherapy have been established as 1L treatment for advanced G/GEJ cancer...
US gastrointestinal malignancies mortality trends among Asian and Pacific Islander populations (1999-2020).
339 Background: Gastrointestinal (GI) cancers are particularly prominent among Asian and Pacific Islander populations and...
Updated results of the phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors.
710 Background: TSN1611 is a novel small molecule KRAS G12D inhibitor targeting both the active (GTP-bound/On) and inactiv...
Impact of total neoadjuvant therapy (TNT) on overall complete response (CR) for locally advanced rectal cancer (LARC): A Brazilian real-world study.
54 Background: There are limited data on the impact of TNT on complete response (CR) rates for LARC treated in community s...
Association between <i>ERBB2</i> (HER2) amplification, RNA gene expression (GE), and immunohistochemistry (IHC) in GI cancers.
23 Background: ERBB2 copy number (CN) and amplification (amp) – assessed with next-generation sequenci...
Preoperative NALIRIFOX versus upfront surgery in high-risk resectable pancreatic cancer: A randomized, multi-center trial.
711 Background: Neoadjuvant therapy is recommended for pancreatic cancer (PC) patients with high-risk features, although n...
Safety and efficacy of hepatic artery infusion chemotherapy (HAIC) or lenvatinib combined with sintilimab as neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular carcinoma: A prospective, randomized, two-cohort, exploratory phase II clinical study.
565 Background: Neoadjuvant treatment is recommended for resectable hepatocellular carcinoma (HCC) with high risk of posto...
Effect of exercise and nutritional prehabilitation on preoperative lean body mass in elderly gastric cancer patients: Results of a randomized controlled trial.
290 Background: Sarcopenia, an age-related decrease of muscle mass and strength, has been reported to be associated with i...
Real-world efficacy and safety of surufatinib in advanced neuroendocrine neoplasm.
634 Background: Surufatinib is an oral tyrosine kinase inhibitor that targets VEGFR1/2/3, FGFR1, and CSF-1R, exerting anti...
Discovery of a functional biomarker for sensitivity to poly ADP ribose polymerase inhibitors (PARPi) in colorectal cancer (CRC).
150 Background: Precision oncology is commonly defined as using information encoded by the tumor genome for the prediction...
Association between obesity, molecular subtype, and immunotherapy outcomes in intrahepatic cholangiocarcinoma: The obesity paradox.
587 Background: Obesity and elevated body mass index (BMI) are associated with increased cancer risk yet paradoxically cor...
Phase I trial of high-dose SBRT combined with atezolizumab and bevacizumab in advanced hepatocellular carcinoma.
560 Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality. In the pivotal IMbrave...
Risk of relapse and lack of benefit from adjuvant chemotherapy following surgical resection of early-stage appendiceal adenocarcinoma.
840 Background: There are no prospective studies evaluating the benefit of adjuvant chemotherapy (AC) for patients diagnos...